Evidence map›Paper›PMID 41160360›Full record

ArticleAMB Express2025

Preparation of a camel-canine chimeric antibody against canine B-cell lymphoma.

Baohui Li, Fuxiang Bao, Yanlong Liu, Qihuan Zhao, Puchen Li, Bo Wang, Guanyi Ren, Yu Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Baohui Li *College of Veterinary Medicine, Inner Mongolia Agricultural University, No. 29, Erdos East Street, Saihan District, Huhhot, 010010, Inner Mongolia Autonomous Region, China.
Fuxiang Bao *College of Veterinary Medicine, Inner Mongolia Agricultural University, No. 29, Erdos East Street, Saihan District, Huhhot, 010010, Inner Mongolia Autonomous Region, China. baofuxiang@imau.edu.cn.
Yanlong LiuBaotou Animal and Plant Quarantine and Animal Disease Prevention and Control Centre, Baotou, 014000, Inner Mongolia Autonomous Region, China.
Qihuan ZhaoCollege of Veterinary Medicine, Inner Mongolia Agricultural University, No. 29, Erdos East Street, Saihan District, Huhhot, 010010, Inner Mongolia Autonomous Region, China.
Puchen LiCollege of Veterinary Medicine, Inner Mongolia Agricultural University, No. 29, Erdos East Street, Saihan District, Huhhot, 010010, Inner Mongolia Autonomous Region, China.
Bo WangCollege of Veterinary Medicine, Inner Mongolia Agricultural University, No. 29, Erdos East Street, Saihan District, Huhhot, 010010, Inner Mongolia Autonomous Region, China.
Guanyi RenCollege of Veterinary Medicine, Inner Mongolia Agricultural University, No. 29, Erdos East Street, Saihan District, Huhhot, 010010, Inner Mongolia Autonomous Region, China.
Yu WangCollege of Veterinary Medicine, Inner Mongolia Agricultural University, No. 29, Erdos East Street, Saihan District, Huhhot, 010010, Inner Mongolia Autonomous Region, China. wangyu@imau.edu.cn.

Funding

Basic scientific research fund of directly affiliated universities in Inner Mongolia Autonomous Region BR250101National Natural Science Foundation of China 32260893Natural Science Foundation of Inner Mongolia Autonomous Region 2022MS03019Program for Young Talents of Science and Technology in Universities of Inner Mongolia Autonomous Region NJYT23094Science and Technology Plan Project of Inner Mongolia Autonomous Region 2023YFXZ0002
6 · The paper itself

Abstract

Canine B-cell lymphoma is a malignant hematologic neoplastic disease, with diffuse large B-cell lymphoma being the predominant subtype. This subtype highly expresses canine CD20 on its surface. Most clinical treatments are chemotherapeutic, with the standard treatment being the CHOP regimen. In immunotherapy, rituximab is effective for treating human B-cell lymphoma. However, its inability to bind natural canine CD20 renders it ineffective in treating canine B-cell lymphoma. The main objective of this study was to establish camel-canine chimeric antibodies and validate their in vitro biological activity. A Bactrian camel was immunized with the CD20 extracellular region peptide. The VHH fragment was amplified using nested PCR, ligated to the phage vector pMECS, and used to construct a phage antibody library with a capacity of 3.4 × 10

Indexed as

Camel-canine chimeric antibodyCanine B-cell lymphomaPhage display technology

Identifiers

PMID41160360
PMCPMC12572584

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.